欢迎您加入月均活跃用户100万＋的科研社区！如您有任何系统建议，请；如有合作推广需求，请点此洽谈。
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | JOURNAL OF CLINICAL ONCOLOGY J CLIN ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.9
53人评分
我要评分
声誉 9.9 影响力 9.9 速度 9.1 | |||||||||||||||||||||
| 期刊ISSN | 0732-183X | 
蝌蝌APP，让您与同行交流更轻松
 立即下载 | ||||||||||||||||||||
| E-ISSN | 1527-7755 | |||||||||||||||||||||
| 2024-2025最新影响因子 （数据来源于搜索引擎） | 41.9 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2025年5月19日：39.19 | |||||||||||||||||||||
| 2024-2025自引率 | 1.90%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 37.7 | |||||||||||||||||||||
| JCI期刊引文指标 | 6.68 | |||||||||||||||||||||
| h-index | 494 | |||||||||||||||||||||
| CiteScore （ 2025年最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://jco.ascopubs.org/ | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/JCO-ASCOPUBS | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足JOURNAL OF CLINICAL ONCOLOGY的语言要求，还能让JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, USA, VA, 22314 | |||||||||||||||||||||
| 出版商 | American Society of Clinical Oncology | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Biweekly | |||||||||||||||||||||
| 出版年份 | 1983 | |||||||||||||||||||||
| 年文章数 | 365点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 27.29% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 93.70% | |||||||||||||||||||||
| WOS期刊JCR分区 （ 2024-2025年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中国科学院《国际期刊预警 名单（试行）》名单 | 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中国科学院期刊分区 （ 2025年3月最新升级版） | 点击查看中国科学院期刊分区趋势图
| |||||||||||||||||||||
| 中国科学院期刊分区 （ 2023年12月升级版） |
| |||||||||||||||||||||
| 中国科学院期刊分区 （ 2022年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0732-183X%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约20% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在JOURNAL OF CLINICAL ONCOLOGY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Reply to: Importance of Defining Recurrence in Hepatocellular Carcinoma: Local or Both Local and Other Intrahepatic Recurrences? Author: Xi, Mian; Fu, Yizhen; Zhang, Yaojun Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 17, pp. -. DOI: 10.1200/JCO-25-00327 PubMed DOI |
| 2. | Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized Controlled Clinical Trial Author: Yao, Han; Huang, Ruihao; Fu, Haixia; Lin, Ren; Zhang, Yanqi; Feng, Yimei; Wang, Yu; Chen, Ting; Wang, Xiaoqi; Zhu, Lidan; Liu, Jia; Liu, Yuqing; Zhao, Lu; Wang, Lu; Kong, Peiyan; Wen, Qin; Zhang, Cheng; Gao, Li; Gao, Lei; Liu, Qifa; Zhang, Xiaohui; Huang, Xiaojun; Zhang, Xi Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 17, pp. -. DOI: 10.1200/JCO-24-02119 PubMed DOI |
| 3. | JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study Author: Xu, Jianmin; Tang, Wentao; Lin, Rongbo; Huang, Xiwen; Zhang, Yanqiao; Qu, Xiujuan; Liu, Hailong; Liu, Zhenyang; Lu, Hongxia; Huang, Jing; Xue, Junli; Liu, Bo; Hao, Jinheng; Yang, Xiugao; Yang, Yang; Su, Yangzhi; Cheng, Jianhong; Wan, Xuechao; Song, Yane; Zhang, Ran Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 17_SUPPL, pp. LBA3516-LBA3516. DOI: 10.1200/JCO.2025.43.17_suppl.LBA3516 DOI |
| 4. | Sentinel lymph node biopsy versus pelvic lymphadenectomy in cervical cancer: The PHENIX trial Author: Tu, Hua; Huang, He; Li, Yanfang; Chen, Xiaojun; Wang, Chunyan; Zhang, Yanna; Zheng, Min; Zhou, Hu; Yu, Aijun; Lv, Weiguo; Xiao, Jing; Li, Ji-Bin; Feng, Weiwei; Kong, Beihua; Wang, Xipeng; Liu, Jihong Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 17_SUPPL, pp. LBA5501-LBA5501. DOI: 10.1200/JCO.2025.43.17_suppl.LBA5501 DOI |
| 5. | Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09 Author: Tolaney, Sara M.; Jiang, Zefei; Zhang, Qingyuan; Barroso-Sousa, Romualdo; Park, Yeon Hee; Rimawi, Mothaffar F.; Saura Manich, Cristina; Schneeweiss, Andreas; Toi, Masakazu; Chae, Yee Soo; Kemal, Yasemin; Chaudhari, Mukesh; Yamashita, Toshinari; Casalnuovo, Monica; Danso, Michael A.; Liu, Jie; Shetty, Jagdish; Herbolsheimer, Pia Maarit; Loibl, Sibylle Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 17_SUPPL, pp. LBA1008-LBA1008. DOI: 10.1200/JCO.2025.43.17_suppl.LBA1008 DOI |
| 6. | Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study Author: Shitara, Kohei; Gumus, Mahmut; Pietrantonio, Filippo; Lonardi, Sara; De La Fouchardiere, Christelle; Coutzac, Clelia; Dekervel, Jeroen; Hochhauser, Daniel; Shen, Lin; Mansoor, Wasat; Liu, Bo; Fornaro, Lorenzo; Ryu, Min-Hee; Lee, Jeeyun; Souza, Fabricio; Jukofsky, Lori; Zhao, Yumin; Kamio, Takahiro; Zaanan, Aziz; Van Cutsem, Eric Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 17_SUPPL, pp. LBA4002-LBA4002. DOI: 10.1200/JCO.2025.43.17_suppl.LBA4002 DOI |
| 7. | Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer Author: Shen, Lin; Peng, Zhi; Li, Changzheng; Lu, Linzhi; Wang, Xiang; Zhang, Jun; Zhang, Yanqiao; Deng, Ting; Sun, Meili; Cai, Dongyan; Jin, Yin; Zong, Hong; Ye, Feng; Xu, Huiting; Zhang, Mingjun; Liu, Jianzhi; Feng, Dan; Fang, Jianmin Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 17_SUPPL, pp. LBA4012-LBA4012. DOI: 10.1200/JCO.2025.43.17_suppl.LBA4012 DOI |
| 8. | Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304 Author: Rudin, Charles M.; Mountzios, Giannis Socrates; Sun, Longhua; Cho, Byoung Chul; Demirci, Umut; Baka, Sofia; Gumus, Mahmut; Lugini, Antonio; Ciuleanu, Tudor-Eliade; Ahn, Myung-Ju; Rocha, Pedro; Zhu, Bo; Blackhall, Fiona Helen; Yoshida, Tatsuya; Owonikoko, Taofeek K.; Paz-Ares, Luis G.; Huang, Shuang; Gauto, Diana Maria; Recondo, Gonzalo; Schuler, Martin Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 17_SUPPL, pp. LBA8008-LBA8008. DOI: 10.1200/JCO.2025.43.17_suppl.LBA8008 DOI |
| 9. | PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC) Author: Picozzi, Vincent J.; Babiker, Hani M.; Chandana, Sreenivasa R.; Melichar, Bohuslav; Kasi, Anup; Jin, Gang; Gallego, Javier; Bullock, Andrea J.; Chunyi, Hao; Wyrwicz, Lucjan; Osipov, Arsen; De La Fouchardiere, Christelle; Dragovich, Tomislav; Lee, Woo Jin; Feeney, Kynan; Philip, Philip; Ueno, Makoto; Van Cutsem, Eric; Seufferlein, Thomas; Macarulla, Teresa Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 17_SUPPL, pp. LBA4005-LBA4005. DOI: 10.1200/JCO.2025.43.17_suppl.LBA4005 DOI |
| 10. | Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III-IV melanoma: Primary results from RELATIVITY-098 Author: Long, Georgina, V; Ascierto, Paolo Antonio; Guo, Jun; Chandra, Sunandana; Tarhini, Ahmad A.; Couselo, Eva Munoz; Del Vecchio, Michele; De Melo, Andreia Cristina; Gogas, Helen; Dummer, Reinhard; Callahan, Margaret K.; Schadendorf, Dirk; Koelblinger, Peter; Quereux, Gaelle; Thomas, Ioannis; Chen, Bohang; Cheong, Alicia Mun Yen; Djidel, Patrick; Dolfi, Sonia; Tawbi, Hussein A Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 17_SUPPL, pp. LBA9500-LBA9500. DOI: 10.1200/JCO.2025.43.17_suppl.LBA9500 DOI |
|
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
